Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly KRd for transplant-eligible newly diagnosed multiple myeloma (real-world, multicenter, China)
ChiCTR2400082476Phase 4Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Start
- Mar 2024
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Beijing Chaoyang Hospital, Capital Medical University. Primary endpoint: Objective response rate (ORR) after 4 cycles. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400082476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082476.